BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ducancelle A, Pivert A, Bertrais S, Boursier J, Balan V, Veillon P, le Guillou-Guillemette H, Thibault V, Castelain S, Roquebert B, Coste-Burel M, Mackiewicz V, Schvoerer E, Larrat S, Maylin S, Alain S, Loustaud-Ratti V, Gordien E, Gozlan J, Brodard V, Chevaliez S, Calès P, Lunel-Fabiani F. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity. J Gastroenterol Hepatol 2016;31:1750-6. [PMID: 26992056 DOI: 10.1111/jgh.13338] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Li F, Li X, Yan T, Liu Y, Cheng Y, Xu Z, Shao Q, Liao H, Huang P, Li J, Chen GF, Xu D. The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection. Hepatol Int 2018;12:107-17. [PMID: 29651701 DOI: 10.1007/s12072-018-9858-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Alidjinou EK, Bocket L, Pigot V, Lambert V, Hallaert C, Canva V, Hober D. Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients. Diagn Microbiol Infect Dis 2018;90:277-9. [PMID: 29310947 DOI: 10.1016/j.diagmicrobio.2017.12.006] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Wang M, Chen L, Dong M, Li J, Zhu B, Yang Z, Gong Q, Han Y, Yu D, Zhang D, Zoulim F, Zhang J, Zhang X. Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerg Microbes Infect 2021;10:842-51. [PMID: 33870846 DOI: 10.1080/22221751.2021.1919033] [Reference Citation Analysis]
4 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
5 Lefeuvre C, Roux M, Blanchard S, Le Guillou-Guillemette H, Boursier J, Lunel-Fabiani F, Jeannin P, Pivert A, Ducancelle A. Analysis of hepatic fibrosis markers in the serum of chronic hepatitis B patients according to basal core promoter/precore mutants. Sci Rep 2022;12:10261. [PMID: 35715541 DOI: 10.1038/s41598-022-14285-9] [Reference Citation Analysis]
6 Li MR, Xu ZG, Lu JH, Zheng HW, Ye LH, Liu YY, Liu ZQ, Zhang HC, Huang Y, Dai EH, Pan CQ. Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. J Viral Hepat 2020;27:1044-51. [PMID: 32384194 DOI: 10.1111/jvh.13315] [Reference Citation Analysis]
7 Shokatpour N, Vaezjalali M, Foster GR, Sali S. Nucleotide Substitutions in Hepatitis B Viruses Derived from Chronic HBV Patients. Mediterr J Hematol Infect Dis 2019;11:e2019046. [PMID: 31308922 DOI: 10.4084/MJHID.2019.046] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Wu JF, Chang KC, Ni YH, Hsu HY, Chang MH. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion. J Infect Dis 2021;223:1381-9. [PMID: 32860707 DOI: 10.1093/infdis/jiaa545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Delaugerre C, Danel C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study. Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa. J Viral Hepat 2018;25:1121-31. [PMID: 29660214 DOI: 10.1111/jvh.12914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Joshi SS, Gao S, Castillo E, Coffin CS. Presence of Precore (C)/C Promoter Mutants in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B (CHB) Carriers During Pregnancy Does Not Correlate with Increased Risk of Liver Disease in 4 Years of Follow-Up. Dig Dis Sci 2020;65:204-14. [PMID: 31376084 DOI: 10.1007/s10620-019-05745-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Boyd A, Lacombe K, Lavocat F, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F. Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients. Antiviral Res 2018;149:174-8. [PMID: 29169914 DOI: 10.1016/j.antiviral.2017.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]